Earnings call
Indoco Remedies Q2 FY25 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The transcript does not name its quarter. Q2 FY25 is worked out from the date it was filed.
The company still expects remediation at the Goa 2 facility to be completed by quarter three; whether FDA coming down will hamper commercial activity from the site remains uncertain because the facility has continued OAI status. The company is looking to incrementally get 50% more output from each factory, with the additional solid-orals output coming from every factory. Net revenues were INR3,946 million in the second-quarter '24-'25, compared to INR3,942 million in the immediate preceding quarter. The company says counters carrying its toothpaste products have increased month-on-month by 15%. The company says roughly 60% of its portfolio goes with FPP and 40% still goes through others.
The numbers management gave
Results
- Net revenues were INR3,946 million in the second-quarter '24-'25, compared to INR3,942 million in the immediate preceding quarter.
Show source
Net revenues of the company for the second-quarter '24-'25 shows muted growth at INR3,946 million compared to INR3,942 million when compared to the immediate preceding quarter.
- EBITDA to net sales was 13.4% at INR529 million for the quarter, compared to 15.6% at INR724 million for the same quarter last year.
Show source
EBITDA to net sales for the quarter is 13.4% at INR529 million compared to 15.6% at INR724 million for the same quarter last year.
What it expects ahead
What management expects
- The company still expects remediation at the Goa 2 facility to be completed by quarter three; whether FDA coming down will hamper commercial activity from the site remains uncertain because the facility has continued OAI status.
Show source
Page 7 of 15 Indoco Remedies Limited October 24, 2024 Aditi Panandikar: We still expect the remediation to get over by quarter three, whether FDA coming down is going to -- or not coming down is going to hamper commercial from this site is something that we have to wait simply because we have continued the OAI status.
- The company expects its two toothpaste products to generate in excess of INR120 crores in the current year, compared with around INR85 crores or INR90 crores when they were in ethical.
Show source
And these two are for the current year, we expect them to do in excess of INR120 crores, which would still be a decent growth over there, you know, I think if I'm not mistaken, when they were in ethical, it was around INR85 crores or INR90 crores.
- The company expects 25% to 30% growth from its two toothpaste products in the second year.
Show source
So I'm very confident and I feel surely and certainly that in the second year, we can definitely expect 25% to 30% growth from these two products itself.
What it is building and selling
Projects and capacity
- The company is looking to incrementally get 50% more output from each factory, with the additional solid-orals output coming from every factory.
Show source
So from every factory 50% more output can come from solid orals.
- The company has increased every batch capacity, reducing associated testing costs and the process time required to manufacture each batch.
Show source
So testing costs associated to it -- with it, process times required to manufacture each batch is being reduced.
Demand and pricing
- The company says counters carrying its toothpaste products have increased month-on-month by 15%.
Show source
But as the awareness with consumer, the reach to consumer, the -- we incidentally now subscribe to Nielsen data also, where we measure what is called weighted or a numerical distribution -- Page 10 of 15 Indoco Remedies Limited October 24, 2024 where we are consistently seeing a 15 -- month-on-month 15% increase in the counters at which the product is being carried.
Segments
- The company says roughly 60% of its portfolio goes with FPP and 40% still goes through others.
Show source
So roughly I would say around 60-40 with 60% going with FPP and 40% still through others.
- Europe business is 90% contracting manufacturing in today’s date, and it says it has 50% of the UK Paracetamol market.
Show source
Europe business is 90% contracting manufacturing in today’s date and in these kind of business if you see in UK the Paracetamol which has been sold of that 50% market is with us.
Risks, rules and outside factors
Outside factors
- The company says raw-material prices were on a decreasing trend, with certain key raw materials at a lower level, and expects the impact to reflect in the next couple of quarters.
Show source
Of course, the impact of the same will reflect going-forward in next couple of quarters.
Everything else said on the call
Group structure
- US business, previously generic support, is now a front end, and the business will be its own in the coming time.
Show source
US business is generic before it was generic support now it is a front end then in the coming time it will be ours.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Pramod Ghorpade: Yes, sure. So Rajat, if you see as compared to quarter 1, the expenses are increased by about INR20-odd crores, particularly in our various sales promotional activities, advertisement, sales promotional activities and travel field, we have increased certain field force and travel-related to that field force is also a part of this other expenses.
Answer, aditi panandikar
Aditi Panandikar: There is also some increase in commissions and incentives since our acute divisions are doing very well.
Answer, aditi panandikar
Aditi Panandikar: Yes. So I think Europe and emerging markets are two different things. But there is one common thing for both these geographies is that both the plants supplying to emerging as well as Europe are also under master manufacturing plan upgradation. So while we have tried our best to stagger it, somehow in Q2, it was not possible anymore to keep things pending as they would have hurt us in future. Just to give you -- and you know our Europe and US plants, although geographically, we say Goa makes for US and Baddi will make for Europe and Bharuch will make for emerging, as part of our attempt to have a very agile operations management system, we are trying to align the portfolios at various locations and therefore whenever a location comes under renovation to meet with the blueprint plan as per the master manufacturing organization, a particular product to both geographies suffers. So somehow in this quarter that has happened and one of our larger manufacturing unit which supplies to Europe, particularly is under remediation, not because regulators want it, but for us, because we have decided that that is now going forward, we'll get far more output from the same unit at much lesser cost per year. Sudarshan: Apart from US, I mean, how far are we in terms of fixing up and ramping up for the other locations, I mean, Europe and US?
Answer, aditi panandikar
Aditi Panandikar: Yes. You are asking for solid oral. Sudarshan: Yes, for the solid oral, I mean, I'm just trying to understand now that as most of the practices and the process has been implemented in the other geographies outside the US. Aditi Panandikar: Yes, what was your question exactly? Sudarshan: Earlier, I mean, we have seen impact in Europe and other regions as well, just any regions and we are basically trying to harmonize if I understand, you know, put things in practice. So I'm just trying to understand, one let's you work with the USFDA, which is mandatory. The others are working because it is more voluntary.
Answer, aditi panandikar
Aditi Panandikar: Yes. Because you know, it depends, I think the perspective is very important to decide what is mandatory and what is necessary and what is voluntary. I think we are all aware of what is happening globally with increase in freights and yo-yoing in cost of goods and particularly in US with the drop-in prices. I think our corporate operations planning has sat together with the business teams of Europe, US as well as emerging markets. And we have made a plan which will allow us to ride through these kinds of rough phases. And therefore, you may say it is voluntary, but we feel it is mandatory, if we are to going-forward show better efficiency and better EBITDA margins, both in Europe as well as US. Page 5 of 15 Indoco Remedies Limited October 24, 2024 Sudarshan: Sure, ma'am.
Answer, aditi panandikar
The next question from my side is on the gross margin. If we are looking at, I mean, the API prices largely my understanding is the chemicals and API prices have remained kind of benign. Would the drop in the gross margin largely be because of the regional mix that we are seeing or are we seeing any kind of a fast escalation on our raw materials?
Answer, aditi panandikar
Aditi Panandikar: Which period you are looking for a drop-in GC? Sudarshan: So I'm primarily looking at the second quarter and probably in comparison with the last year as well as this.
Answer, aditi panandikar
Aditi Panandikar: Okay, gross margins and COGS are other operating. So because at least two large plants are under this kind of staggering shutdown planned or compulsory. The operating costs at those sites other than the material costs are of a fixed nature, right? So they remain. So that is how the margins get impacted. Is that your question? Sudarshan: Yes that explains below the gross margin, but we have also seen the raw-material price has increased.
Answer, sundeep bambolkar
Sundeep V Bambolkar: So Mr. Sudarshan, if you see the raw-material prices, the overall trend is on a decreasing side. Of course, not significantly, but certainly we are looking at certain key raw materials at a lower level. Of course, the impact of the same will reflect going-forward in next couple of quarters.
Answer, aditi panandikar
Aditi Panandikar: But yes, product mix does matter. Because you know, as of now, with steriles being really down and whatever business for US has come, it's come from solid orals. So naturally that impact would be seen in the GCs, A. B, also like we have explained in earlier calls, the company is in a transformational phase. In the past, quite a substantial portion of our revenues for end markets used to come from milestones as well as royalties or profit share, etcetera, but less of profit share and more of milestone. Now that Indoco has a front-end in US of our own and we are therefore keeping IP for ourselves, there is minuscule amount that is coming from that. So rather than the GCs have gone down, the entire sort of portfolio mix or product mix of the business has changed. So in order to keep margins for us in the future, we are kind of foregoing milestones currently.
Answer, aditi panandikar
Aditi Panandikar: See, I think you can appreciate the last two quarters, at least Q1 was alright. We saw some impact of these supply constraints. Q2 has taken a maximum impact. Q3, why we remain optimistic, I have to say there would be certain constraints. So at this stage, I would want to wait for another quarter before I give guidance for the future. Sudarshan: Sure ma'am. One final question before I join the queue.
Answer, aditi panandikar
If I look at the data on the brands that you had given in the press and also the AIOCD data, the growth that we are seeing, it looks like our brands are doing fairly well in the secondary market, but the primary sales is a little lesser. I mean, one is what would be the reason and should we see a catch-up playing going-forward? I Page 6 of 15 Indoco Remedies Limited October 24, 2024 mean, should the secondary start reflecting as the primary data in terms of better growth as we start moving towards the third and fourth quarter?
Answer, aditi panandikar
Aditi Panandikar: Okay. I think when you say secondaries are good, you are looking at IQVIA and Pharmarack data and primarily we are looking at internal. Is that it? Sudarshan: Yes.
Answer, aditi panandikar
Aditi Panandikar: So I think when you look at the internal data of IRL standalone, you have to factor in the aspect that two large toothpastes are now with the 100% subsidiary Warren Remedies. So the base sale of these two toothpaste continues to be there in last year's sales, which is why if you look at growth on primary, it would appear that we have not grown. Does that answer your question? Sudarshan: That answers mine. Thanks a lot, ma'am. I'll join back the queue.
Question
Ankit Minocha: So this is regarding a notification that was put out. There was another visit by the FDA on Goa 2 facility and there was an OAI indication. This was also the status in the past. So what exactly happened here and when do the plants get back to the other remediation that getting over and the plants getting back to running.
Answer, aditi panandikar
Aditi Panandikar: Yes. So in 2023, we were audited by USFDA. And after that au dit, the plant was classified as OAI. While there were not any issues directly related to data integrity, cleaning validations or any such procedures, a sterile unit FDA had cautioned because they felt that the plant was old and certain areas need remodelling so that more space is created. Also, some of our lines were very old and FDA expected us to move from Glove Ports to the future isolator baselines, etcetera. And therefore, we were classified as OAI. After that, we have submitted outlined plan to USFDA of how and when we propose to make these changes and complete the job.
Answer, aditi panandikar
And accordingly, routine updates have been going to USFDA. As for this plan, much of the workforce to be completed by the end of 2024 and now to was surprised USFDA once again came in July 2024. While the lines were actually opened up and are not ready for any kind of audit, etcetera. And from the object, there were seven observations, and we have responded to those observations. And again, we have got the same. So basically, the way w e look at it is once all the remediations online is over. USFDA is likely to come back for an audit before it can change the classification of the site.
Answer, ankeet pandya
Ankeet Pandya: Yes. It mostly does, so just -- in that case I believe the earlier con-calls you are expecting this remediation to get done by maybe Q3. So, does that then now put a delay on the entire process and by when do we expect the facility to... Page 7 of 15 Indoco Remedies Limited October 24, 2024 Aditi Panandikar: We still expect the remediation to get over by quarter three, whether FDA coming down is going to -- or not coming down is going to hamper commercial from this site is something that we have to wait simply because we have continued the OAI status.
Answer, aditi panandikar
But our technical teams are in continuous dialogue with USFDA to try and understand their concerns and understand how we have to move forward now. Because I don't know if there were some -- the FDA walked on they misunderstood and felt that we would be ready in November '23 and not November '24, which was really odd because all our a communication said November '24 or later.
Answer, ankeet pandya
Ankeet Pandya: Okay. All right. My second question is any comment on I mean if I look at operating margin on a consolidated level, I mean, I look at the times in 2015 to even 2018-19 where these margins were over around much higher levels and currently the quarter from the consol level, the OPM is 9%. So, I just wanted to understand from your top view of the business, where do you see this number kind of the OPM on a consolidated level, where do you see this number go for this year or as well as next year, if you can out grind some sort of trajectory considering all the challenges of the business?
Answer, aditi panandikar
Aditi Panandikar: Right. So, like I said to one of the earlier questions. At this stage, we are not very -- we don't feel is a right time to make give guidance. But I can help you understand why the, consolidated picture is the way it is. So, for consolidation, we have two subsidiaries for which sales are consolidated to the company, which matter more. One is Warren Remedies, which is taking two of our toothpaste OTC, and also manufactures a few intermediate APIs for us, for Indoco. The second is the subsidiary FPP, which is Florida Pharma, which is our vehicle for launching product in US.
Answer, aditi panandikar
So, Florida Pharma, if actually quarter-on-quarter has made great progress since its acquisition only more than just about a year, more than a year ago, year and a half ago. And we feel very confident in the next six months, especially after the supplies to US start smoothly, we expect the drain happening through FPP on the corporate to come down. Coming to Warren, where the two toothpaste are in the market, this is a phase whereas part of the whole OTC, product launch awareness, digital marketing, television marketing, certain expenses especially on the promotion side are a little bit higher, but that is something which cannot be delayed. As a consequence of that, Warren Remedies is also on the negative and the consolidated picture appears like this more because the parent Indoco revenues are very short in comparison to the running cost for the organization. As explained earlier because our international business has not been able to, we have not been able to supply and collect revenues against international business. Okay.
Answer, aditi panandikar
Abhishek: Okay. So the European part is done, the emerging market part is done. US is current -- and were there any repeat observations? So currently we received like seven observations and… Aditi Panandikar: No, no, none were repeat.
Answer, aditi panandikar
Abhishek: Okay. And like will this take like another one year to again get again this classification changed.
Answer, aditi panandikar
Aditi Panandikar: No. I don't think it should take one year. Had they not come in July, I feel in the -- by the -- by Q1 of '25, they would have -- would have been the latest when they would have come down. Now that they've just come in July, we will stay optimistic to bring them down. And also, we are in talks with them to understand and I don't think current supply is out of that site. So once the site comes up and gets remediated totally and fully ready, I don't see why we have to wait for FDA audits to start supply. Abhishek: But we won't be getting new approvals?
Answer, aditi panandikar
Aditi Panandikar: Yes. But that is not -- yes, we have enough approvals and actually our order book both for US and Europe is very healthy. So that is not very disturbing and neither are we missing out on any big deadlines for any para forth. So that is not a big concern right now. Right now, for me, the urgency with which we can finish the projects and there are four lines. So, one-line is up actually just now as we speak. And every 15 days, a line will come up.
Answer, aditi panandikar
So, the question is whether FDA will want for all four lines to be going before they agree to come down. Can we – we are asking for a call with them since they have recently commenced in our site. You would like to understand if they have any other concerns, all that is going on and I'm hoping in the next call, when I speak with you, I can give you a much better guidance. Abhishek: So Q3 also, there will be improvement sequentially compared to Q2 because Europe is done ?
Answer, aditi panandikar
Aditi Panandikar: Not -- yes. So, US business is not all about sterile for us. We do have a solid oral plant, which is plant one and there is a small amount of business we have currently of solids that also work is going on to ramp it up. So , there will be improvement surely. But as you rightly said, Q4 would be probably a better time for us to see upside coming from smooth functioning of plant. Abhishek: So on the Europe part, it is completely done now and in Q3 also, it's on full ramp -up?
Answer, aditi panandikar
Aditi Panandikar: Europe is almost done, yes. Abhishek: But yes, revenues haven't started like optimally what… Aditi Panandikar: They were impacted, rather.
Question
Ma'am, my first question, I have couple of questions. The first one is, related to the OPC, like what is the advert of it or the promotional expenses have been added to the other expenses. As OTC products, these are all for the OTC products, right? So going- forward, like this OTC products we will keep on adding and so this -- will these expenses, this promotional expenses be there going-forward?
Answer, aditi panandikar
Aditi Panandikar: So typically, if you are aware there are various categories of products, so you are frank ethical, then you have BTC as it's called behind the counter, then you have OTX and then you have frank OTC. So depending on where your product is positioned, the amount of expenditure that is required is different. Not all the products we intend to take beyond ethical will always go frank OTC. These two toothpastes had to go frank OTC because the largest competitor we have, which is Sensodyne has almost close to 70% of its revenues coming from channel outside ethical, that is chemist, meaning they sell at grocers, they sell with modern trade and they sell even with the panwala. So we have to go there and since this kind of a supply-chain expansion, a shift in the structure of how goods are distributed in order to keep your new SDs. And new purchase partners and the GTs, that is the grocer's sort of positive on the product because they don't know this product, right? The chemists know the product because it's been prescribed for doggone years.
Answer, aditi panandikar
So for this channel partners also to get confidence, the company has planned strategically the kind of inputs that we would require specifically advertising on television and digital spend on YouTube, Facebook, etcetera. And we have been doing that. Coming to your question, future products as they come -- as they go OTC, will this spend remain? No, it doesn't mean that with every product, this kind of a spend is there. Also, sometimes for the first time when a company goes OTC, such a spend is required and that's what we are doing.
Question
Anik Mitra: So maybe a small component may be there. A small component may be there.
Answer, aditi panandikar
Aditi Panandikar: You know, if I were you, I would concentrate on growth in sales because we have one OTC because the whole thing about doing OTC is getting a much larger market from which to get share. And while this expenditure initially is like an investment and we should be prepared for that. Yes.
Question
Anik Mitra: And my next question is, what kind of revenue addition can you expect from this OTC product in FY '26?
Answer, aditi panandikar
Aditi Panandikar: So the two -- right now only two toothpastes are there with some various SKUs as in pack sizes, but largely we are just two. And these two are for the current year, we expect them to do in excess of INR120 crores, which would still be a decent growth over there, you know, I think if I'm not mistaken, when they were in ethical, it was around INR85 crores or INR90 crores. So this is the first year. But as the awareness with consumer, the reach to consumer, the -- we incidentally now subscribe to Nielsen data also, where we measure what is called weighted or a numerical distribution -- Page 10 of 15 Indoco Remedies Limited October 24, 2024 where we are consistently seeing a 15 -- month-on-month 15% increase in the counters at which the product is being carried. These are all kind of foundation activities to prepare for a much larger sale as we go ahead. So I'm very confident and I feel surely and certainly that in the second year, we can definitely expect 25% to 30% growth from these two products itself.
Question
Anik Mitra: Ma'am, do you position your products in this tooth paste with the normal toothpaste or do you place -- like consider it as only the peer of Sensodyne?
Answer, aditi panandikar
Aditi Panandikar: No, not necessarily only, Sensodyne, but sensitivity market. And as per Nielsen, in the sensitivity market, we are number two to Sensodyne.
Answer, aditi panandikar
Aditi Panandikar: Yes. Thank you for the question. So no in answer to your question, not all products which were licensed out are being brought in, but further products are not getting licensed out. So the milestones, therefore, are not coming in. We have some excellent relationships with front end - - other front end partners in US with whom we are quite happy, especially in the solid oral space and those continue. Much of the ophthalmic and sterile opportunities though we would prefer to do through FPP going forward. Many of the products which we had licensed out to Teva, for Page 11 of 15 Indoco Remedies Limited October 24, 2024 example, are now back with us as part of the arrangement and those are also being relaunched through FPP.
Question
Dhwanil Desai: Yes. So approximately what percentage of your portfolio now is back to you and now going through front end, existing one?
Answer, aditi panandikar
Aditi Panandikar: See, volume and value are two different things because you will get volume in solid orals and value in ophthalmic. So roughly I would say around 60-40 with 60% going with FPP and 40% still through others.
Question
Dhwanil Desai: Okay. And that 40% is now currently everything is now through FPP?
Answer, aditi panandikar
Aditi Panandikar: No. 60% would be through FPP, 40% is currently with other partners.
Question
Dhwanil Desai: So 60% is already done by our own front end, currently?
Answer, aditi panandikar
Aditi Panandikar: Yes, plan to be done, once the supply chain does.
Question
Ankur Agarwal: Good evening, ma'am. The capacities which we have and the product line which we have, if we remove the temporary pains then in the coming 3 years, 4 years what growth management predict under the company in operating profits and toplines?
Answer, aditi panandikar
Aditi Panandikar: Thank you for the question. You have asked the correct question. The kind of things that I said earlier literally we are looking at incrementally getting 50% more from each of our sites -- each of the factories. So from every factory 50% more output can come from solid orals. Not only that every batch capacity has been increased. So testing costs associated to it -- with it, process times required to manufacture each batch is being reduced. And I would not like to unnecessarily commit, but I'm actually hoping that as the numbers come out, you will see the beauty of what this kind of restructuring does, but if you understand our business India business is branded and emerging market business is also branded.
Answer, aditi panandikar
US business is generic before it was generic support now it is a front end then in the coming time it will be ours. Europe business is 90% contracting manufacturing in today’s date and in these kind of business if you see in UK the Paracetamol which has been sold of that 50% market is with us. So such a big market we have capture then when this efficiency increases directly through company medium the benefits comes from this and we are waiting for these kind of beautiful things to come out and show by way of profitability. Page 12 of 15 Indoco Remedies Limited October 24, 2024 Ankur Agarwal: Then also internal targets in 3 to 4 years where did it reached?
Answer, aditi panandikar
Aditi Panandikar: We are expecting from an EBITDA perspective at least great increment to happen. But because of what we are going through right now. You all can understand that I would prefer to wait for one more quarter before I give you these numbers. Ankur Agrawal: Okay. And in US Biosecure Act which has been passed or will pass will we get a benefit from that?
Answer, aditi panandikar
Aditi Panandikar: Biosecure Act CDMO business which is there and India might get the plenty and direct impact from a manufacturing side bio generic and bio pharmaceuticals in today situation then we can’t get the direct manufacturing advantage, but associated with the research is there like contract research to do parts of the work, analytical research, analytical services division is there and related to that bio studies the business which CRO will get that advantages we can get.
Questions about this call
- When was the Indoco Remedies Q2 FY25 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 28 Oct 2024. This page is built from that transcript.
- What does this page list?
- 12 statements from the transcript across 7 topics, 8 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 10 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.